JP6464085B2 - 神経膠芽腫の治療のための併用療法 - Google Patents

神経膠芽腫の治療のための併用療法 Download PDF

Info

Publication number
JP6464085B2
JP6464085B2 JP2015526648A JP2015526648A JP6464085B2 JP 6464085 B2 JP6464085 B2 JP 6464085B2 JP 2015526648 A JP2015526648 A JP 2015526648A JP 2015526648 A JP2015526648 A JP 2015526648A JP 6464085 B2 JP6464085 B2 JP 6464085B2
Authority
JP
Japan
Prior art keywords
vegf
antibody
treatment
human
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015526648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525798A (ja
JP2015525798A5 (OSRAM
Inventor
アシャ ダース，
アシャ ダース，
アナ マリア アバーホ ギハーロ，
アナ マリア アバーホ ギハーロ，
ローレン オーブリー，
ローレン オーブリー，
ジュゼップ ガルシア，
ジュゼップ ガルシア，
マガリー ヒルトン，
マガリー ヒルトン，
ヤニック ケールロークエン，
ヤニック ケールロークエン，
ニコラ ムーア，
ニコラ ムーア，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48985869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6464085(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2015525798A publication Critical patent/JP2015525798A/ja
Publication of JP2015525798A5 publication Critical patent/JP2015525798A5/ja
Application granted granted Critical
Publication of JP6464085B2 publication Critical patent/JP6464085B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)
JP2015526648A 2012-08-07 2013-08-06 神経膠芽腫の治療のための併用療法 Active JP6464085B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261680672P 2012-08-07 2012-08-07
US61/680,672 2012-08-07
US201261714438P 2012-10-16 2012-10-16
US61/714,438 2012-10-16
US201361760763P 2013-02-05 2013-02-05
US61/760,763 2013-02-05
PCT/US2013/053841 WO2014025813A1 (en) 2012-08-07 2013-08-06 Combination therapy for the treatment of glioblastoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017128609A Division JP2018008946A (ja) 2012-08-07 2017-06-30 神経膠芽腫の治療のための併用療法

Publications (3)

Publication Number Publication Date
JP2015525798A JP2015525798A (ja) 2015-09-07
JP2015525798A5 JP2015525798A5 (OSRAM) 2017-08-17
JP6464085B2 true JP6464085B2 (ja) 2019-02-06

Family

ID=48985869

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015526648A Active JP6464085B2 (ja) 2012-08-07 2013-08-06 神経膠芽腫の治療のための併用療法
JP2017128609A Withdrawn JP2018008946A (ja) 2012-08-07 2017-06-30 神経膠芽腫の治療のための併用療法
JP2019079205A Pending JP2019147812A (ja) 2012-08-07 2019-04-18 神経膠芽腫の治療のための併用療法
JP2021078365A Pending JP2021138704A (ja) 2012-08-07 2021-05-06 神経膠芽腫の治療のための併用療法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017128609A Withdrawn JP2018008946A (ja) 2012-08-07 2017-06-30 神経膠芽腫の治療のための併用療法
JP2019079205A Pending JP2019147812A (ja) 2012-08-07 2019-04-18 神経膠芽腫の治療のための併用療法
JP2021078365A Pending JP2021138704A (ja) 2012-08-07 2021-05-06 神経膠芽腫の治療のための併用療法

Country Status (15)

Country Link
US (2) US20150148585A1 (OSRAM)
EP (2) EP3446709A1 (OSRAM)
JP (4) JP6464085B2 (OSRAM)
KR (3) KR20150038593A (OSRAM)
CN (1) CN104507498A (OSRAM)
AU (3) AU2013299724A1 (OSRAM)
BR (1) BR112015002681A2 (OSRAM)
CA (1) CA2880767A1 (OSRAM)
HK (1) HK1204993A1 (OSRAM)
IL (2) IL237028B (OSRAM)
MX (1) MX360189B (OSRAM)
RU (1) RU2015104001A (OSRAM)
SG (1) SG11201500903XA (OSRAM)
WO (1) WO2014025813A1 (OSRAM)
ZA (1) ZA201500811B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220053691A (ko) 2013-03-15 2022-04-29 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
SG11201606714TA (en) * 2014-02-14 2016-09-29 Andrew S Chi Improved methods for the treatment of vascularizing cancers
JP6983511B2 (ja) * 2014-04-25 2021-12-17 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 脳中の転移乳癌および他の癌を処置するための方法および組成物
CA2946906A1 (en) * 2014-05-07 2015-11-12 Medimmune, Llc Methods of using anti-ang2 antibodies
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RU2715038C2 (ru) 2014-07-11 2020-02-21 Дженентек, Инк. Антитела анти-pd-l1 и способы их диагностического применения
JP2017523776A (ja) 2014-07-14 2017-08-24 ジェネンテック， インコーポレイテッド 膠芽腫の診断方法及びその治療用組成物
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
BR112019026435A2 (pt) 2017-06-12 2020-07-14 Agios Pharmaceuticals, Inc. métodos de tratamento de tumores cerebrais usando terapia de combinação
CN119280245A (zh) 2017-06-12 2025-01-10 法国施维雅药厂 使用组合疗法治疗脑肿瘤的方法
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
SI1516628T1 (sl) 1995-07-27 2013-10-30 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
SI1695985T1 (sl) 1997-04-07 2011-06-30 Genentech Inc Postopki za tvorbo humaniziranih protiteles z naključno mutagenezo
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
CA2393869A1 (en) 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
RS20050885A (sr) 2003-05-30 2008-04-04 Genentech Lečenje sa anti-vegf antitelima
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AR060871A1 (es) 2006-05-09 2008-07-16 Genentech Inc Union de polipeptidos con supercontigos optimizados
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
SG175289A1 (en) * 2009-04-20 2011-11-28 Genentech Inc Adjuvant cancer therapy
MX2012009554A (es) * 2010-02-23 2012-11-23 Hoffmann La Roche Terapia anti-angiogenesis para el tratamiento del cancer ovarico.
AU2011293522B2 (en) * 2010-08-24 2015-03-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US20120114638A1 (en) * 2010-11-08 2012-05-10 John Boylan Combination therapy

Also Published As

Publication number Publication date
RU2015104001A (ru) 2016-09-27
WO2014025813A1 (en) 2014-02-13
US20150148585A1 (en) 2015-05-28
ZA201500811B (en) 2016-10-26
KR20180011356A (ko) 2018-01-31
JP2015525798A (ja) 2015-09-07
KR20190088571A (ko) 2019-07-26
AU2018253461A1 (en) 2018-11-15
EP2882454B1 (en) 2018-10-10
BR112015002681A2 (pt) 2018-08-28
AU2016244262A1 (en) 2016-11-03
US20200086139A1 (en) 2020-03-19
AU2013299724A1 (en) 2015-02-26
KR20150038593A (ko) 2015-04-08
AU2016244262B2 (en) 2018-07-26
CN104507498A (zh) 2015-04-08
IL237028B (en) 2019-03-31
JP2021138704A (ja) 2021-09-16
EP2882454A1 (en) 2015-06-17
JP2019147812A (ja) 2019-09-05
JP2018008946A (ja) 2018-01-18
MX360189B (es) 2018-10-24
IL263661A (en) 2019-01-31
MX2015001627A (es) 2015-06-23
EP3446709A1 (en) 2019-02-27
HK1204993A1 (en) 2015-12-11
CA2880767A1 (en) 2014-02-13
SG11201500903XA (en) 2015-03-30

Similar Documents

Publication Publication Date Title
JP6464085B2 (ja) 神経膠芽腫の治療のための併用療法
JP6640288B2 (ja) 卵巣癌の治療のための併用療法
CN105611939A (zh) 用于治疗成胶质细胞瘤的组合疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170228

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170630

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170831

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190107

R150 Certificate of patent or registration of utility model

Ref document number: 6464085

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250